Riskpilot← Back to searchSign inGet full accessVetInject A/S
A/SActiveCVR 36949740Strandvejen 60, 5.Manufacture of medical and dental instruments and supplies · NACE 3250Est. 2015— employeeswww.vetinject.com
Revenue 2025
DKK -137K
-12% vs 2024
EBITDA margin
100.0%
+12% vs 2024
Equity ratio
18.6%
Financial strength
Net profit 2025
DKK -172K
+29% vs 2024
| Revenue | DKK -137K | -12% |
| EBITDA | DKK -137K | +12% |
| Net profit | DKK -172K | +29% |
| Total assets | DKK 283K | -19% |
| Equity | DKK 53K | -77% |
| Employees | — | — |
Legal name
VetInject A/S
CVR number
36949740
Legal form
Aktieselskab
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
18. juni 2015
Share capital
DKK 600.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-08-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør og 2 bestyrelsesmedlemmer i forening, den samlede bestyrelse eller af den administrerende direktør og bestyrelsesformanden i forening.
Company purpose
Virksomhedens formål er at drive virksomhed med udvikling, markedsføring og distribution af injektions redskaber på veterinærområdet med hovedvægt på redskaber til præfyldning med veterinær medicin og dermed efter bestyrelsens opfattelse beslægtet virksomhed.
Address
Strandvejen 60, 5.
Email
th@vetinject.com
Website
www.vetinject.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -152 | -120 | -141 | -136 | -143 | -139 | -155 | -135 | -155 | -137 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -152 | -120 | -141 | -136 | -143 | -139 | -155 | -135 | -155 | -137 |
| Depreciation & amort. | -26 | -29 | -27 | -27 | -27 | -27 | -27 | -20 | -27 | -27 |
| EBIT | -178 | -148 | -168 | -163 | -170 | -166 | -182 | -155 | -182 | -164 |
| Net financials | 0 | 0 | -16 | -17 | -21 | -31 | -37 | -32 | -58 | -8 |
| Profit before tax | -178 | -148 | -184 | -180 | -191 | -197 | -219 | -187 | -241 | -172 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -178 | -148 | -184 | -180 | -191 | -197 | -219 | -187 | -241 | -172 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 535 | 511 | 464 | 408 | 939 | 883 | 792 | 783 | 350 | 283 |
| Equity | 422 | 274 | 90 | -90 | 319 | 121 | -98 | -285 | 225 | 53 |
| Long-term debt | 0 | 125 | 259 | 388 | 510 | 649 | 777 | 0 | 0 | 0 |
| Short-term debt | 113 | 237 | 374 | 499 | 620 | 762 | 889 | 1.067 | 125 | 230 |
| Total debt | 113 | 237 | 374 | 499 | 620 | 762 | 889 | 1.067 | 125 | 230 |
EBITDA margin
-13734800.0%
This company
15.8%
Market median
-86929214% vs market
20162025
Equity ratio
18.6%
This company
38.2%
Market median
-51% vs market
20162025
Return on equity
-326.0%
This company
18.4%
Market median
-1872% vs market
20162025
Net profit margin
-17190300.0%
This company
8.1%
Market median
-212226026% vs market
20162025
Asset turnover
-0.49×
This company
1.12×
Market median
-144% vs market
20162025
Debt / equity
4.37×
This company
0.62×
Market median
-605% vs market
20162025
- Annual report 2025Filed via CVR / Virk · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via CVR / Virk · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via CVR / Virk · Period 2022-12-01 – 2023-08-31
- Annual report 2022Filed via CVR / Virk · Period 2021-12-01 – 2022-11-30
- Annual report 2021Filed via CVR / Virk · Period 2020-12-01 – 2021-11-30
- Annual report 2020Filed via CVR / Virk · Period 2019-12-01 – 2020-11-30
- Annual report 2019Filed via CVR / Virk · Period 2018-12-01 – 2019-11-30
- Annual report 2018Filed via CVR / Virk · Period 2017-12-01 – 2018-11-30
- Annual report 2017Filed via CVR / Virk · Period 2016-12-01 – 2017-11-30
- Annual report 2016Filed via CVR / Virk · Period 2015-06-18 – 2016-11-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TH Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
JF Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
AL Founder | Founder | 2015 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2015 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2015 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Injecto Group A/S | Company | 100.0% | 100.0% | 2023 |
AC Management ApS | Company | 10.0% | 10.0% | 2018 |
Ametex IVS | Company | 10.0% | 10.0% | 2015 |
SØBORG EL ApS | Company | 5.0% | 5.0% | 2020 |
Torben Helmer ApS | Company | 10.0% | 10.0% | 2020 |
CV 1 INVEST ApS | Company | 10.0% | 10.0% | 2015 |
| Individual | 33.3% | 33.3% | 2020 | |
Tina Hetting Holding I ApS | Company | 25.0% | 25.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
DOPEN HOLDING ApS
VetInject A/S Board members of VetInject A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Torben Helmer Knudsen | Chief Executive Officer | 0 companies |
| Jan Frydenriech Fogh | Chief Executive Officer | 0 companies |
| ASYRINGE LIMITED COMPANY | Founder | 0 companies |
| Emil Bue Bredel | Chairman | 0 companies |
| Mikael Hans Andranik Hetting | Chairman | 0 companies |
| Thomas Sonne-Schmidt | Board of Directors | 0 companies |
| John Holger Adamsen | Chairman | 0 companies |
| Carsten Sylvester Larsen | Board of Directors | 0 companies |